Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research

NCT06711146 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Metabolically Armed CD19 CAR-T cells

Sponsor

Zhejiang University

Collaborators

[object Object]